secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2023-03-14T23:59:59+00:00
Accession:  0001558370-23-003644
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx reports 2022 net loss $129.6M; pipeline advances toward 2024 BLA
-------------------------------------------------------------------------

- Net loss of $129.6M ($2.87/share) vs $79.6M in 2021; revenue $15.9M (down from $37.7M on lower milestone payments).
- Cash and equivalents $115.5M plus $21M Janssen receivables; expected runway into Q4 2024.
- Phase 3 Lumeos trial for botaretigene sparoparvovec (XLRP) enrolling; BLA submission on track for 2024.
- AAV-hAQP1 for xerostomia showed 75% symptom improvement; Phase 2 planned Q2 2023.
- AAV-GAD for Parkinson's dosing patients; enrollment completion anticipated Q3 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837023003644/0001558370-23-003644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837023003644/mgtx-20230314x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-003644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer